.jpg "Corcept Therapeutics Inc (NASDAQ: CORT)")
Today, a Director at Corcept Therapeutics Inc, Leonard G. Baker, exercised options of Corcept Therapeutics Inc for $480.3K. The options were close to expired and Leonard G. Baker disposed stocks.
See today’s analyst top recommended stocks >>
Based on Corcept Therapeutics Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $57.66 million and quarterly net profit of $17.46 million. In comparison, last year the company earned revenue of $27.6 million and had a net profit of $4.39 million. CORT’s market cap is $1.98B and the company has a P/E ratio of 15.32. Currently, Corcept Therapeutics Inc has an average volume of 1.61M.
Three different firms, including BMO Capital and Merrill Lynch, currently also have a Sell rating on the stock.
The insider sentiment on Corcept Therapeutics Inc has been positive according to 15 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K.
